PPARG and systemic sclerosis: However, because PPAR-γ agonists have off-target and ligand-independent effects [6, 20–24], approaches designed to selectively target the PPAR-γ pathway may provide an alternative way to modulate fibrogenesis in SSc without the adverse side effects of PPAR-γ agonists.